# Flavonoid Glycosides from Terminalia catappa L.

Yun-Lian Lin<sup>a,\*</sup> ( ${}^{a}L\P^{31/2}$ ), Yueh-Hsiung Kuo<sup>b</sup> ( ${}^{3}\phi \circledast \P^{-}$ ), Ming-Shi Shiao<sup>c</sup> ( ${}^{1/2} \square u^{\circ 3}$ ),

Chien-Chih Chen<sup>a</sup> ( ${}^{3-}$ «Ø§Ó) and Jun-Chih Ou<sup>a</sup> ( ${}^{1/4}U^{1/4}I^{a}U$ )

<sup>a</sup>National Research Institute of Chinese Medicine, Taipei 112, Taiwan. R.O.C.

<sup>b</sup>Department of Chemistry, National Taiwan University, Taipei 106, Taiwan. R.O.C.

<sup>c</sup>Department of Medical Research and Education, Veterans General Hospital, Taipei 112, Taiwan. R.O.C.

Under the inhibition of Cu<sup>+2</sup>-induced LDL oxidation-guided fractionation, two new flavone glycosides with galloyl substitution were isolated from the dried fallen leaves of *Terminalia catappa* L. Their structures were established as apigenin 6-*C*-(2"-*O*-galloyl)- $\beta$ -*D*-glucopyranoside (**1**) and apigenin 8-*C*-(2"-*O*-galloyl)- $\beta$ -*D*-glucopyranoside (**2**), together with four known flavone glycosides, isovitexin, vitexin, isoorientin, and rutin, on the basis of spectroscopic method. Compounds **1** and **2** showed significant antioxidative effects. Their IC<sub>50</sub> were 2.1 and 4.5  $\mu$ M, respectively.

#### INTRODUCTION

The dried fallen leaves of Terminalia catappa L. (Combretaceae) are a commonly used folk medicine in Taiwan. It has been claimed to have therapeutic effects for liver related diseases.<sup>1</sup> Hydrolyzable ellagitannins and other tannin related compounds have been isolated from the leaves and the bark of *T.catappa*.<sup>2,3</sup> Several tannins were shown inhibiting HIV replication in infected H9 lymphocytes with little cytotoxicity.<sup>4</sup> Liu et al. have shown the water extract of the leaves of T. catappa suppressed mitomycin C-induced micronuclei in CHO-K1 cells. It was suggested that its in vitro and in vivo anticlastogenic effects may be attributed to its antioxidative potential.<sup>5</sup> And many studies have provided supporting evidence that Chinese medicine used on blood stasis and hepatic injury contains antioxidants to prevent LDL lipid peroxidation.<sup>6-8</sup> Therefore, we investigated the chemical constituents under the antioxidation-guided fractionation of its leaves. This paper deals with the isolation of two new flavone C-glycosides with galloyl substitution and their antioxidant activities.

### **RESULTS AND DISCUSSION**

The ethanol extract of the dried fallen leaves of *T. catappa* suspended in water was successively partitioned with ethyl acetate and *n*-butanol. The *n*-butanol soluble fraction was subjected to separation and purification on Diaion HP-20 and Sephadex LH-20 column chromatography, and led to the

isolation of two new glucosides **1** and **2** together with four known flavonoid glycosides, isovitexin (**3**), <sup>9,10</sup> vitexin (**4**), <sup>9,10</sup> isoorientin (**5**), <sup>11</sup> and rutin (**6**), <sup>12</sup> gallic acid and ellagic acid.

Compound 1 was isolated as yellow amorphous powder. The molecular formula was established as C<sub>28</sub>H<sub>24</sub>O<sub>14</sub> from FABMS  $[m/z 585 (M + H)^+]$  and <sup>13</sup>C NMR data. The IR spectrum showed hydroxyl (3350 cm<sup>-1</sup>), ester (1705, 1220 cm<sup>-1</sup>), conjugated carbonyl (1650 cm<sup>-1</sup>), and aromatic (1610, 1500 cm<sup>-1</sup>) absorption bands. The UV absorptions at 270, 336 nm, showed that compound **1** was a flavone derivative.<sup>13</sup> The <sup>1</sup>H and <sup>13</sup>C NMR (Table 1) spectrum contained signals due to a galloyl moiety:  $\delta_{\rm H}$  6.79 (s, 2H);  $\delta_{\rm C}$  108.6, 108.6, 119.8, 137.9, 145.2, 145.2 and 165.3. Without the galloyl moiety, it was similar to that of apigenin 6-C-glucoside [isovitexin (3)].<sup>9,10</sup> A para-substituted phenol was characterized by the  $A_2X_2$  pattern  $[\delta 6.89 \text{ and } 7.86 \text{ (each 2H, d, } J = 8.7 \text{ Hz})]$  for four aromatic protons. Two singlet protons [( $\delta$  6.41 and 6.68 (each 1H, s)] were assigned as H-8 and H-3 from HMQC and HMBC correlations, and an anomeric proton with larger coupling constant  $(\delta 4.89, d, J = 9.9 \text{ Hz})$  had a long-range correlation with C-6. A methine proton at  $\delta$  5.65 (dd, J = 9.9, 8.5 Hz) had a C-H correlation with glucosyl C-2 and a long range correlation with the carbonyl of galloyl. These indicated that the galloyl was connected with C-2 hydroxyl of the glucosyl. Therefore, compound 1 was determined as apigenin  $6-C-(2''-O-galloyl)-\beta$ --D-glucopyranoside.

The NMR spectral data together with the molecular ion at  $m/z 585 (M + H)^+$  in FABMS indicated that **2** was closely related to **1** except that one of the singlet phenyl protons in **2** was higher field at  $\delta$  6.09. This suggested that the glucosylated po-

Dedicated to the memory of the late Professor Ta-shue Chou ( <sup>©</sup>P¤j ÓV)

E.P.S.



- 1  $R_1 = C \beta D$ -glucosyl(2"-galloyl),  $R_2 = R_3 = R_4 = H$
- 2  $R_1 = R_3 = R_4 = H$ ,  $R_2 = C \beta D$ -glucosyl(2"-galloyl)
- 3  $R_1 = C \beta D$ -glucosyl,  $R_2 = R_3 = R_4 = H$
- 4  $R_1=R_3=R_4=H$ ,  $R_2=C-\beta$ -D-glucosyl
- 5  $R_1 = C \beta D$ -glucosyl,  $R_2 = R_4 = H$ ,  $R_3 = OH$

sition was changed from C-6 to C-8 in **2**. That was further supported by a correlation between the proton at  $\delta$  6.09 and C-6 ( $\delta$  98.1) in HMQC spectrum and a correlation between strong hydrogen bonding of the C-5 hydroxyl proton and C-6 in the

HMBC spectrum.

The known compounds **3**, **4**, and **5** were confirmed by direct comparison of their spectral data with values reported in the literature,  $9\cdot11$  and compound **6**, gallic acid and ellagic acid were identified by direct comparison with authentic samples.

The isolated compounds were tested for antioxidative activity on  $\text{Cu}^{+2}/\text{O}_2$ -induced low density lipoprotein (LDL) lipid peroxidation with probucol (IC<sub>50</sub> 4.0  $\mu$ M)as positive control. The inhibitory effects of a more potent antioxidant showed dose response curves. The IC<sub>50</sub> of compounds **1** and **2** are 2.1 and 4.5  $\mu$ M, respectively.

### EXPERIMENTAL

Melting points were determined on a Yanagimoto micromelting point apparatus and are uncorrected. IR spectra were recorded on a Perkin-Elmer 781 spectrophotometer. NMR spectra were run on a Bruker AC-300 in DMSO-d<sub>6</sub>. UV spectra were taken on a Hitachi U-3200 spectrophotometer. MS were measured on a FINNIGAN TSQ-46C MS spectrometer. Pobucol was obtained from Merrell Dow. Cupric sulfate

Table 1. <sup>1</sup>H NMR Spectral Data for Flavonoids **1-6** from *T*. *Catappa* (in DMSO-d<sub>6</sub>,  $\delta$ )

H-position	1	2	3	4	5	6
3	6.68s	6.73s	6.75s	6.62s	6.63s	
6		6.09s		6.27s		6.18d
						( <i>J</i> =2.0)
8	6.41s		6.51s		6.46s	6.37d
						( <i>J</i> =2.0)
2′	7.86d	8.09d	7.91d	8.01d	7.38d	7.52d
	( <i>J</i> =8.7)	( <i>J</i> =8.7)	( <i>J</i> =8.4)	( <i>J</i> =8.4)	( <i>J</i> =2.0)	( <i>J</i> =2.0)
3'	6.89d	6.93d	6.93d	6.89d		
	( <i>J</i> =8.7)	( <i>J</i> =8.7)	(J=8.4)	(J=8.4)		
5'	6.89d	6.93d	6.93d	6.89d	6.88d	6.83d
	( <i>J</i> =8.7)	( <i>J</i> =8.7)	(J=8.4)	(J=8.4)	( <i>J</i> =7.8)	( <i>J</i> =9.0)
6'	7.86d	8.09d	7.91d	8.01d	7.44dd	7.53dd
	( <i>J</i> =8.7)	( <i>J</i> =8.7)	(J=8.4)	( <i>J</i> =8.4)	( <i>J</i> =7.8,	( <i>J</i> =9.0,
					2.0)	2.0)
1″	4.89d	4.94d	4.61d	4.68d	4.59d	5.33d
	( <i>J</i> =9.9)	( <i>J</i> =10.2)	( <i>J</i> =9.9)	( <i>J</i> =9.9)	( <i>J</i> =9.6)	( <i>J</i> =6.9)
1‴						4.39br s
2″	5.65dd	5.48dd	4.03dd		4.02dd	
-	( <i>J</i> =9.9.	( <i>J</i> =10.2.	( <i>J</i> =9.9.		( <i>J</i> =9.6.	
	8.5)	9.3)	8.4)		8.4)	
CH <sub>3</sub>		,,	,		,	0.99d
						(J=6.0)
galloyl-H	6.79s	6.67s				
	(2H)	(2H)				
ОН	9.43br s	9.21br s	9.58br s	10.26br s	9.31br s	9.51br s
	10.25br s	10.42br s	10.25br s	10.73br s	9.811br s	9.87br s
	10.25 br s	10.98br s	13.53br s	13.14br s	10.43br s	10.25brs
	12.62br s	13.08brs			13.53br s	12.56br s
				0.		

Table 2 <sup>13</sup>C NMR Spectral Data for Flavonoids **1-6** from *T. catappa* (in DMSO-d<sub>6</sub>,  $\delta$ )

<sup>13</sup> C-position	1	2	3	4	5	6
2	164.5	165.2	163.5	163.9	163.6	165.8
3	102.8	102.8	102.8	102.4	102.8	133.6
4	181.7	182.2	181.9	182.0	181.8	177.3
5	161.1	162.5	161.2	161.0	160.6	156.9
6	107.0	98.1	108.8	98.1	108.8	99.4
7	163.6	164.4	163.2	162.5	163.2	161.1
8	93.7	104.1	93.7	104.6	93.5	94.3
9	156.3	156.7	156.2	155.9	156.2	156.8
10	105.7	104.1	103.4	104.0	103.4	103.7
1′	121.5	122.0	121.1	121.5	121.4	122.0
2'	130.3	129.3	128.4	128.8	113.3	116.4
3'	115.9	116.2	116.0	115.7	145.7	144.9
4'	160.8	161.3	160.6	160.3	149.7	148.7
5'	115.9	116.2	116.0	115.7	116.0	115.9
6'	130.3	129.3	128.4	128.8	118.9	130.3
glc-1	70.7	71.4	73.1	73.3	73.1	101.8
glc-2	72.0	72.5	70.6	70.8	70.6	74.3
glc-3	76.4	76.2	78.9	78.8	78.9	76.6
glc-4	70.7	71.0	70.3	70.5	70.3	70.7
glc-5	81.7	82.1	81.4	81.7	81.4	76.1
glc-6	61.3	61.3	61.4	61.3	61.4	67.3
rha-1						101.1
rha-2						70.2
rha-3						70.7
rha-4						72.1
rha-5						68.5
rha-6						17.9
galloyl						
1	119.8	119.8				
2,6	108.6	108.9				
3,5	145.2	145.4				
4	137.9	138.4				
C=O	165.3	165.2				

(CuSO<sub>4</sub>), and EDTA were purchased from Sigma Chemical Co. Cholesterol kit (Merkotest, 14366 cholesterol enzymatic) was obtained from Merck. Ultracentrifugation were taken on a Beckman L8-80M; R50 rotor.

#### **Plant Materials**

The dried fallen leaves of *Terminalia catappa* were collected in Taitung. and identified by comparison with the specimens which have been deposited at the Herbarium of the Department of Botany, National Taiwan Unversity, Taipei, Taiwan.

### **Extraction and Isolation**

The dried fallen leaves of *T. catappa* (6 Kg) were extracted exhaustively with ethanol. Under the inhibition of  $Cu^{+2}$ -induced LDL lipid peroxidation-guided fractionation, the ethanol extract suspended in water was partitioned with ethyl acetate (EtOAc) and *n*-butanol (BuOH), successively. The BuOH soluble fractions (131 g) were subjected to separa-

tion and purification by Diaion HP-20 (H<sub>2</sub>O-MeOH gradient). The 50% MeOH, 75% MeOH and MeOH eluates were further purified by Sephadex LH-20 (MeOH or 80% MeOH/H<sub>2</sub>O) column to afford **1** (275 mg), **2** (65 mg), isovitexin (46 mg), vitexin (256 mg), isoorientin (43 mg), rutin (36 mg), gallic acid (156 mg) and ellagic acid (452 mg).

### Apigenin 6-C-(2"-galloyl)- $\beta$ -D-glucoside (1)

Yellow amorphous powder; FABMS *m/z*: 585 (M+1)<sup>+</sup>; IRv<sub>max</sub>(KBr) cm<sup>-1</sup>: 3350, 1705, 1650, 1610, 1500, 1220, 1180, 1060, 1030, 830; UV  $\lambda_{max}$  (MeOH)(log  $\epsilon$ ) 270 (3.97), 336 (3.80) nm;  $\lambda_{max}$  (MeOH+AlCl<sub>3</sub>) (log  $\epsilon$ ) 279 (3.95), 302 (3.96), 337 (3.87), 382 (3.78) nm;  $\lambda_{max}$  (MeOH + AlCl<sub>3</sub> + HCl) (log  $\epsilon$ ) 279 (4.00), 293 (3.94), 345 (3.90), 371(3.87) nm;  $\lambda_{max}$ (MeOH + NaOAc) (log  $\epsilon$ ) 273 (3.97), 297 (3.88), 349 (3.91) nm;  $\lambda_{max}$ (MeOH + NaOAc+H<sub>3</sub>BO<sub>3</sub>) (log  $\epsilon$ ) 272 (3.96), 297 (3.95), 348 (3.95) nm; <sup>1</sup>H NMR (DMSO-d<sub>6</sub>): Table 1; <sup>13</sup>C NMR (DMSO-d<sub>6</sub>): Table 2.

### Apigenin 8-C-(2"-galloyl)-β-D-glucoside (2)

Yellow amorphous powder; FABMS *m/z*: 585 (M+1)<sup>+</sup>; IRv<sub>max</sub> (KBr) cm<sup>-1</sup>: 3400, 1705, 1650, 1605, 1510, 1220, 1180, 1050, 1035, 835; UV  $\lambda_{max}$  (MeOH) (log  $\varepsilon$ ) 271 (3.95), 293sh (3.86), 313 (3.85) nm;  $\lambda_{max}$  (MeOH+AlCl<sub>3</sub>) (log  $\varepsilon$ ) 278 (4.03), 302 (4.02), 322 (3.89), 383 (3.88) nm;  $\lambda_{max}$  (MeOH + AlCl<sub>3</sub> + HCl) (log  $\varepsilon$ ) 277 (4.08), 301 (4.02), 344 (3.90), 378 (3.89) nm;  $\lambda_{max}$  (MeOH + NaOAc) (log  $\varepsilon$ ) 273 (4.20), 304 (4.06), 335 (3.91)nm;  $\lambda_{max}$  (MeOH + NaOAc + H<sub>3</sub>BO<sub>3</sub>) (log  $\varepsilon$ ) 272 (4.15), 301 (4.17), 348 (3.92) nm; <sup>1</sup> H NMR (DMSO-d<sub>6</sub>): Table 1; <sup>13</sup>C NMR (DMSO-d<sub>6</sub>): Table 2.

### **Isovitexin (3)** 9,10

Yellow amorphous powder; FABMS m/z: 433 (M+1)<sup>+</sup>; IRv<sub>max</sub> (KBr) cm<sup>-1</sup>: 3300, 1655, 1610, 1590, 1515, 1500, 1085, 1020, 835; UV  $\lambda$  max (MeOH) (log  $\varepsilon$ ) 272 (3.86), 331 (3.71) nm;  $\lambda$  max (MeOH + AlCl<sub>3</sub>) (log  $\varepsilon$ ) 280 (3.87), 294 (3.84), 344 (3.67), 380 (3.65) nm;  $\lambda$  max (MeOH + AlCl<sub>3</sub> + HCl) (log  $\varepsilon$ ) 278 (3.92), 297 (3.75), 347 (3.73), 383 (3.70) nm; <sup>1</sup>H NMR (DMSO-d<sub>6</sub>): Table 1; <sup>13</sup>C NMR (DMSO-d<sub>6</sub>): Table 2.

## Vitexin (4) 9,10

Yellow amorphous powder; FABMS m/z: 433 (M+1)<sup>+</sup>; IRv<sub>max</sub>(KBr) cm<sup>-1</sup>: 3400, 1660, 1605, 1590, 1510, 1500, 1080, 1030, 830; UV  $\lambda$  max (MeOH) (log  $\varepsilon$ ) 270 (3.89), 334 (3.89) nm;  $\lambda$  max (MeOH + AlCl<sub>3</sub>) (log  $\varepsilon$ ) 276 (3.88), 304 (3.76), 345 (3.88), 386 (3.76) nm;  $\lambda$  max (MeOH + AlCl<sub>3</sub> + HCl) (log  $\varepsilon$ ) 277 (3.88), 303 (3.76), 343 (3.88), 384 (3.76) nm; <sup>-1</sup>H NMR (DMSO-d<sub>6</sub>): Table 1; <sup>13</sup>C NMR (DMSO-d<sub>6</sub>): Table 2.

### **Isoorientin** (5)<sup>11</sup>

Yellow amorphous powder; FABMS m/z: 449 (M+1)<sup>+</sup>; IRv<sub>max</sub> (KBr) cm<sup>-1</sup>: 3400, 1660, 1630, 1580, 1510, 1090, 1035, 840; UV  $\lambda_{max}$  (MeOH) (log  $\varepsilon$ ) 257 (3.99), 271 (4.02), 349 (4.03) nm;  $\lambda_{max}$  (MeOH + AlCl<sub>3</sub>) (log  $\varepsilon$ ) 276 (4.13), 300sh (3.80), 333 (3.74), 424 (4.15) nm;  $\lambda_{max}$  (MeOH + AlCl<sub>3</sub> + HCl) (log  $\varepsilon$ ) 263sh (3.96), 278 (4.00), 294 (3.90), 361 (3.99), 386 (3.99) nm; <sup>1</sup>H NMR (DMSO-d<sub>6</sub>): Table 1; <sup>13</sup>C NMR (DMSO-d<sub>6</sub>): Table 2.

## **Rutin** (6)<sup>12</sup>

Yellow crystals, mp 241-243 °C; FABMS m/z: 611(M + 1)<sup>+</sup>; IRv<sub>max</sub> (KBr) cm<sup>-1</sup>: 3400, 1660, 1600, 1500, 1060, 1015, 805; <sup>1</sup>H NMR (DMSO-d<sub>6</sub>): Table 1; <sup>13</sup>C NMR (DMSO-d<sub>6</sub>): Table 2.

#### LDL Lipid Peroxidation and Screening for Antioxidants

Fasting plasma samples were collected from healthy male adults not using vitamin supplements. LDL was obtained by following a previously reported method.<sup>14</sup> LDL assay was carried out in a 96 well microtiter plate as described.<sup>15</sup> Probucol (5-20  $\mu$ M, 10% ethanolic solution, 10  $\mu$ l) was used as a positive control. The conjugated diene formation in the supernatant was determined by UV absorption at 232 nm.

### ACKNOWLEDGEMENTS

This work was supported in part by the National Health Research Institutes of the Republic of China (NHRI 86-HR-515).

Received October 27, 1999

#### **Key Words**

*Terminalia catappa* L.; Combretaceae; Dried fallen leaves; Flavone glucopyranosides; Antioxidant.

### REFERENCES

- 1. Chiu, N. Y.; Chang, K. H. *The Illustrated Medicinal Plants of Taiwan*, SMC Publishing, Inc.: Taipei, **1986**, vol.1, p 129.
- Tanaka, T.; Nonaka, G. I.; Nishioka, I. *Chem. Pharm. Bull.* 1986, 34, 1039.
- 3. Lin, T. C.; Hsu, F. L. J. Chin. Chem. Soc. 1999, 46, 613.
- Tanaka, T.; Nonaka, G. I.; Nishizawa, M.; Yamagishi, T.; Kashiwada, Y.; Dutschman, G. E.; Bodner, A. J.; Kilkuskie, R. E.; Cheng, Y. C.; Lee, K. H. J. Nat. Prod. 1990, 53, 587.
- Liu, T. Y.; Ho, L. K.; Tsai, Y. C.; Chiang, S. H.; Chao, T. W.; Li, J. H.; Chi, C. W. *Cancer Letter* **1996**, *105*, 113.
- Recknagel, R. O.; Glende, E. A.; Dolak, J. A.; Waller, R. L. *Pharmac. Ther.* 1989, 43, 139.
- Yagi, A.; Fujimoto, K.; Tanonaka, K.; Hirai, K.; Takeo, S. *Planta Med.* **1989**, *55*, 51.
- 8. Kosuge, T.; Ishide, H.; Yamazaki, H.; Ishii, M. *Yakugaku Zasshi* **1984**, *104*, 1050.
- Numata, A.; Hokimoto, K.; Yamaguchi, H. Chem. Pharm. Bull. 1980, 28, 964.
- Agrawal, P. K. Carbon-13 NMR of Flavonoids, Elsevier Science Publishing Co. Inc.: New York, 1989, pp 283-364.
- 11. Kato, T., Morita, Y. Chem. Pharm. Bull. 1990, 38, 2277.
- 12. Lin, Y. L.; Wang, K. J. J. Taiwan Pharmac. Assoc. 1987, 39, 33.
- Mabry, T. J.; Markham, K. R.; Thomas, M. B. *The Systematic Identification of Flavonoids*, "SSpringer-Verlag, New York, Heidelberg, Berlin, **1970**, pp 41-61.
- Chen, Y. H.; Shiao, Huang, Y. L.; Shen, C. C.; Lin, Y. L.; Kuo, Y. H.; Chen, C. C. J. Nat. Prod. 1999, 62, 1225.
- Wallin, B.; Rosengren, B.; Shertzer, H. G.; Camejo, G. Anal. Biochem. 1993, 208, 10.

